Product Information
BROMOCRIPTINE 2.5 MG TABLET is a generic product labeled by Padagis US LLC, priced at $1.6095 per EA under NDC 00574010601. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 1, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Padagis US LLCNDC
00574010601
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BROMOCRIPTINE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA077646FDA Approved
10/1/2008
TE Code
AB
On Market Since
4/1/2014
Pharmacological Classes
Price Statistics
The NADAC for BROMOCRIPTINE 2.5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 15.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.6095 per EA |
|---|---|
| All-time high | $3.3049 (Apr 12, 2017) |
| All-time low | $0.9986 (May 22, 2024) |
| 52-week high | $1.7958 |
| 52-week low | $1.6058 |
| Median price | $1.7756 |
| Average price | $2.0021 |
| Largest weekly change | +124.0% (Jan 22, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bromocriptine mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Ergot Derivative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BROMOCRIPTINE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BROMOCRIPTINE 2.5 MG TABLET, manufactured by Padagis US LLC, is $1.6095 per EA (NDC 00574010601), effective Sep 30, 2026.
How has the price of BROMOCRIPTINE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BROMOCRIPTINE 2.5 MG TABLET has risen 15.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BROMOCRIPTINE 2.5 MG TABLET?
Since Nov 28, 2013, the NADAC for BROMOCRIPTINE 2.5 MG TABLET has ranged from a low of $0.9986 (May 22, 2024) to a high of $3.3049 (Apr 12, 2017), with a median of $1.7756 per EA.
Are there cheaper alternatives to BROMOCRIPTINE 2.5 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BROMOCRIPTINE 2.5 MG TABLET, is $1.5691 per EA — about 3% below BROMOCRIPTINE 2.5 MG TABLET.
Who manufactures BROMOCRIPTINE 2.5 MG TABLET?
BROMOCRIPTINE 2.5 MG TABLET (NDC 00574010601) is labeled by Padagis US LLC, and CMS classifies it as a generic product.